March 27, 2018 / 8:20 PM / 4 months ago

BRIEF-FDA Advisory Committee Votes In Favor Of Lucemyra

March 27 (Reuters) -

* FDA ADVISORY COMMITTEE VOTES IN FAVOR OF LUCEMYRA™ (LOFEXIDINE) FOR THE MITIGATION OF OPIOID WITHDRAWAL SYMPTOMS

* US WORLDMEDS - IF APPROVED, LOFEXIDINE WILL BE MARKETED UNDER BRAND NAME LUCEMYRA​

* US WORLDMEDS - FDA PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE VOTED 11 TO 1 TO RECOMMEND LOFEXIDINE APPROVAL FOR MITIGATING OPIOID WITHDRAWAL SYMPTOMS

* US WORLDMEDS SAYS FDA HAS SET PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE FOR LUCEMYRA IN Q2 2018

* US WORLDMEDS​ - ‍ADVISORY COMMITTEE’S DISCUSSIONS BASED ON CO’S NDA FOR LUCEMYRA Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below